Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Safety, and Pharmacokinetics of QAW039

Phase 2

Completed

Conditions: Persistent Asthma

Interventions: Drug: Placebo to QAW039 capsules once daily for 28 days
Drug: Fluticasone propionate inhaler twice daily for 28 days
Drug: QAW039 capsules once daily for 28 days

First Posted Date: 2010-12-03

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 170

Registration Number: NCT01253603

Locations: 🇺🇸
Novatis Investigative Site, Upland, Pennsylvania, United States
🇷🇴
Novartis Investigative Site, Bucharest, Romania

Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome

Phase 2

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: AFQ056
Drug: Placebo

First Posted Date: 2010-12-03

Last Posted Date: 2020-12-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 175

Registration Number: NCT01253629

Locations: 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Phase 4

Completed

Conditions: Myelodysplastic Syndrome
Thalassemia

Interventions: Drug: Deferasirox

First Posted Date: 2010-12-01

Last Posted Date: 2016-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT01250951

Locations: 🇷🇺
Novartis Investigative Site, St. Petersburg, Russian Federation

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Phase 2

Completed

Conditions: Dry Eye

Interventions: Biological: Secukinumab 10 mg/kg
Biological: Canakinumab 10 mg/kg
Biological: Placebo

First Posted Date: 2010-11-30

Last Posted Date: 2013-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 72

Registration Number: NCT01250171

Locations: 🇺🇸
Ora Inc, 300 Brickstone Square,, Andover, Massachusetts, United States

Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients

Completed

Conditions: Breast Cancer
Letrozole

First Posted Date: 2010-11-29

Last Posted Date: 2015-06-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 392

Registration Number: NCT01249456

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).

Phase 2

Completed

Conditions: TNF-receptor Associated Periodic Syndromes (TRAPS)

Interventions: Drug: ACZ885

First Posted Date: 2010-11-17

Last Posted Date: 2016-02-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT01242813

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Panobinostat

First Posted Date: 2010-11-17

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT01242774

Locations: 🇺🇸
Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
🇺🇸
Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States
🇺🇸
Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3, Nashville, Tennessee, United States

and more 3 locations

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: LCL161
Drug: Paclitaxel

First Posted Date: 2010-11-15

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT01240655

Locations: 🇺🇸
Dana Farber Cancer Institute SC, Boston, Massachusetts, United States
🇺🇸
University of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, North Carolina, United States
🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

and more 1 locations

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Phase 1

Terminated

Conditions: Metastatic Cancer With Impaired Renal Function
Metastatic Cancer With Normal Renal Function

Interventions: Drug: ASA404

First Posted Date: 2010-11-15

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT01240642

Locations: 🇧🇪
Novartis Investigative Site, Wilrijk, Belgium

Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Ali/Amlo 150/2.5 mg

First Posted Date: 2010-11-10

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT01237873

Locations: 🇯🇵
Novartis Investigative Site, Toshima-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy